CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of -$10.77 million as of 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Debt
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2026-08-05
- 2026-06-27: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net -$10.77M.
- 2026-03-28: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net -$11.62M.
- 2025-12-27: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net -$12.47M; Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net as first filed $12.47M.
- 2025-09-27: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net -$13.32M.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net as first filed |
|---|---|---|
| 2026-06-27 | -$10.77M 10-Q · filed 2026-08-05 | |
| 2026-03-28 | -$11.62M 10-Q · filed 2026-05-07 | |
| 2025-12-27 | -$12.47M 10-Q · filed 2026-08-05 | $12.47M 10-K · filed 2026-02-18 |
| 2025-09-27 | -$13.32M 10-Q · filed 2025-11-05 | |
| 2025-06-28 | -$14.16M 10-Q · filed 2025-08-06 | |
| 2025-03-29 | -$15.01M 10-Q · filed 2025-05-07 | |
| 2024-12-28 | $15.86M 10-K · filed 2026-02-18 | |
| 2024-09-28 | -$11.68M 10-Q · filed 2024-11-06 | |
| 2024-06-29 | -$12.67M 10-Q · filed 2024-08-07 | |
| 2024-03-30 | -$13.66M 10-Q · filed 2024-05-09 | |
| 2023-12-30 | $14.65M 10-K · filed 2025-02-19 | |
| 2023-09-30 | -$15.64M 10-Q · filed 2023-11-08 | |
| 2023-07-01 | -$16.63M 10-Q · filed 2023-08-09 | |
| 2023-04-01 | -$17.63M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $18.62M 10-K · filed 2024-02-14 | |
| 2022-09-24 | -$19.69M 10-Q · filed 2022-11-02 | |
| 2022-06-25 | -$20.70M 10-Q · filed 2022-08-03 | |
| 2022-03-26 | -$21.68M 10-Q · filed 2022-05-04 | |
| 2021-12-25 | $22.66M 10-K · filed 2023-02-22 | -$22.66M 10-K · filed 2022-02-16 |
| 2021-09-25 | -$23.66M 10-Q · filed 2021-11-03 | |
| 2021-06-26 | -$24.65M 10-Q · filed 2021-08-04 | |
| 2021-03-27 | -$18.08M 10-Q · filed 2021-05-04 | |
| 2020-12-26 | -$14.35M 10-K · filed 2022-02-16 | |
| 2020-09-26 | -$15.25M 10-Q · filed 2020-10-29 | |
| 2020-06-27 | -$16.16M 10-Q · filed 2020-08-05 | |
| 2020-03-28 | -$17.07M 10-Q · filed 2020-05-07 | |
| 2019-12-28 | -$17.98M 10-K · filed 2021-02-17 | |
| 2019-09-28 | -$13.78M 10-Q · filed 2019-11-06 | |
| 2019-06-29 | -$14.59M 10-Q · filed 2019-07-31 | |
| 2019-03-30 | -$15.40M 10-Q · filed 2019-05-07 | |
| 2018-12-29 | -$16.21M 10-K · filed 2020-02-11 | $16.21M 10-K · filed 2019-02-13 |
| 2018-09-29 | $17.07M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $17.89M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $8.35M 10-Q · filed 2018-05-10 | |
| 2017-12-30 | $5.77M 10-K · filed 2019-02-13 | |
| 2017-09-30 | $6.23M 10-Q · filed 2017-11-09 | |
| 2017-07-01 | $6.70M 10-Q · filed 2017-08-09 | |
| 2017-04-01 | $7.16M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $7.63M 10-K · filed 2018-02-13 | |
| 2016-09-24 | $8.14M 10-Q · filed 2016-11-02 | |
| 2015-12-26 | $6.80M 10-K · filed 2017-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |